In a new job - May 7, 2015
Lundbeck Hires Novo Exec
The man considered most likely to take over the helm at Novo Nordisk, Kåre Schultz, had a good reason for suddenly leaving the company. He accepted the top job at Lundbeck, which has been without a chief executive since its CEO left amid controversy in November 2014. Lundbeck announced Schultz’s appointment Wednesday along with first-quarter […]
Financing - May 7, 2015
Medivir Bd. to Repurchase Shares
Medivir AB’s board of directors plans to use the authorization given at the annual general meeting to repurchase class B company shares. The repurchases will be carried out in batches over time, but will conclude prior to the next annual general meeting. The execution of the repurchases will depend on market conditions, according to BioSpace.com, […]
Uncategorized - May 7, 2015
Health Tech Event in Helsinki
The largest health technology event in the Nordic countries is scheduled for May 19 in Finland. The Upgraded Life Festival will bring together professionals from healthcare, wellness, big data in health, quantified self, biohacking, fitness, health in wearables and Internet of Things. Events include speakers, panel discussions, clinics and opportunities for networking. Participants will gather […]
Clinical Trials - May 6, 2015
Kidney Cancer Drug Trial Starts
Immunicum has started its phase II clinical study of Intuvax, a therapeutic vaccine for metastatic kidney cancer. Intuvax is based on a technology developed by Immunicum’s research director and founder Alex K-Parra. It involves using dendritic cells from healthy blood donors in order to get the patients ‘ own immune systems to eliminate cancer cells. […]
Acquisition - May 6, 2015
AZ Partnering with Flagship
Venture capital and creation firm Flagship Ventures has formed three new strategic partnerships withAstraZeneca, Nestlé Health Science and Bayer CropScience. Flagship, which manages $1.4 billion in capital, is perhaps best known for the eight successful IPOs it has backed in the past two years, as well as the formation of 27 companies to date, according […]
Clinical Trials - May 5, 2015
Transplant Drug Shows Promise
Veloxis Pharmaceuticals’ once-daily Envarsus® XR (tacrolimus extended-release tablets), an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, demonstrated that a lower, once-a-day dose of Envarsus XR in African-American kidney transplant patients is sufficient to achieve therapeutic tacrolimus blood concentrations, compared to twice-daily immediate release tacrolimus. The […]
